Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.67 |
| ▸ | CES2 | O00748 | 1/20 | 0.67 |
| ▸ | GALR3 | O60755 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CASP1 | P29466 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | GSTA1 | P08263 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.55 |
| ▸ | MPO | P05164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromocyl SCHEMBL10785692 | 0.88 | KDM4E (0.56) | HPGDALOX15CES2GALR3CYP1A2 | |
| SCHEMBL2724103 | 0.84 | HPGD (0.62) | HPGDALOX15CES2GALR3CYP1A2 | |
| SCHEMBL24148132 | 0.84 | HPGD (0.62) | HPGDALOX15CES2GALR3CYP1A2 | |
| SCHEMBL3526226 | 0.83 | GAA (0.55) | HPGDALOX15CES2GALR3CYP1A2 | |
| Bromocyl SCHEMBL11127125 | 0.83 | KDM4E (0.51) | HPGDALOX15CES2GALR3CYP1A2 | |
| SCHEMBL1648464 | 0.82 | HPGD (0.60) | HPGDALOX15CES2GALR3CYP1A2 | |
| Dibromsalan SCHEMBL29496335 | 0.81 | PLAU (0.73) | HPGDALOX15CES2GALR3CYP1A2 | |
| Dibromsalan SCHEMBL646973 | 0.81 | PLAU (0.73) | HPGDALOX15CES2GALR3CYP1A2 | |
| SCHEMBL7943952 | 0.81 | KCNMA1 (0.60) | HPGDALOX15CES2GALR3CYP1A2 | |
| SCHEMBL9312494 | 0.81 | EGFR (0.61) | CES2GAAKDM4EMPOSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
| US-20250041439-A1 | ANTIBODY-DRUG CONJUGATES | SPIREA LIMITED (GB) | 2025-02-06 | — | — | US | disclosed |
| EP-4404974-A1 | ANTIBODY-DRUG CONJUGATES | Spirea Limited (GB) | 2024-07-31 | — | — | EP | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-117597327-A | Pharmaceutical preparation | 第一波动生物制药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2023118074-A1 | COMPRESSIBLE AND FREE FLOWING CO-PROCESSED MESOPOROUS SILICA | UNIVERZA V LJUBLJANI (SI) | 2023-06-29 | — | — | WO | disclosed |
| EP-0120402-B1 | BASE PRECURSOR | FUJI PHOTO FILM CO., LTD. (JP) | 1987-11-11 | — | — | EP | disclosed |
| EP-0120661-B1 | HEAT DEVELOPABLE COLOR LIGHT-SENSITIVE MATERIALS | FUJI PHOTO FILM CO., LTD. (JP) | 1987-05-27 | — | — | EP | disclosed |
| US-4637902-A | BASE PRECURSORS | FUJI PHOTO FILM CO., LTD. (JP) | 1987-01-20 | — | — | US | disclosed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | disclosed |
| US-4511650-A | Heat developable color light-sensitive materials with base releasors | FUJI PHOTO FILM CO., LTD. (JP) | 1985-04-16 | — | — | US | disclosed |
| EP-0120402-A1 | Base precursor | FUJI PHOTO FILM CO., LTD. (JP) | 1984-10-03 | — | — | EP | disclosed |
| EP-0120661-A2 | Heat developable color light-sensitive materials | FUJI PHOTO FILM CO., LTD. (JP) | 1984-10-03 | — | — | EP | disclosed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | HPGD 101/4885ALOX15 460/4885CES2 1771/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | HPGD 1241/4885ALOX15 1507/4885CES2 1738/4885 |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | HPGD 9/4885ALOX15 233/4885CES2 181/4885 |
| US-20250041439-A1 | ANTIBODY-DRUG CONJUGATES | CD44, CD47, FCGR3B | HPGD 4312/4885ALOX15 4576/4885CES2 2256/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | HPGD 92/4885ALOX15 444/4885CES2 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.